发布时间：2025-12-23 14:13 Ustekinumab BS Subcutaneous Injection 45mg Syringes NIPRO has been granted marketing approval in Japan
First marketing approval under the partnership with NIPRO CORPORATION, paving the way for expanding treatment option for patients in Japan
‘NIPRO’ will be commercially available following its listing on the National Health Insurance (NHI) drug price list in May 2026
INCHEON, Korea--(BUSINESS WIRE)--Samsung Bioepis Co., Ltd. today announced the marketing approval ofUstekinumab BS Subcutaneous Injection 45mg Syringes 'NIPRO', a biosimilar referencing Stelara1(ustekinumab), developed by Samsung Bioepis. This is the first product to gain marketing approval in Japan under the partnership with NIPRO CORPORATION entered in June 2025.





“Japan allocates about 10% of its GDP to healthcare2, one of the highest among OECD countries which is why biosimilars are playing an increasingly important role in alleviating the financia
=*=*=*=*=*=
当前为第1/4页
下一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页